Shinichi Nakatoh1, Kenji Fujimori2, Shigeyuki Ishii3, Junko Tamaki4, Nobukazu Okimoto5, Sumito Ogawa6, Masayuki Iki7. 1. Department of Orthopedic Surgery, Asahi General Hospital, 477, Tomari, Asahimachi, Shimo-Niikawa-gun, Toyama, 939-0798, Japan. nakato38@cosmo21.net. 2. Department of Health Administration and Policy, Tohoku University School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan. 3. Department of Regulatory Science, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1, Horinouchi, Hachiouji, Tokyo, 192-0392, Japan. 4. Department of Hygiene & Public Health, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki, Osaka, 569-8686, Japan. 5. Okimoto Clinic, 185-4, Kubi, Yutaka-machi, Kure-city, Hiroshima, 734-0304, Japan. 6. Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. 7. Department of Public Health, Kindai University Faculty of Medicine, 377-2, Oono-Higashi, Osaka Sayama city, Osaka, 589-8511, Japan.
Abstract
Test and treatment rates for osteoporosis in Japan aimed at preventing secondary fragility fractures were insufficient. Those who suffered hip fractures had approximately half the rates of those who suffered vertebral fractures, with such rates being lower among those over 80 years old and males. PURPOSE: The present study aimed to examine the care gap for secondary fracture prevention in Japan given the few large-scale studies regarding the matter. METHODS: Changes in bone mineral density testing (test rate) and osteoporosis pharmacotherapy administration (treatment rate) rates before and after hip and vertebral fracture registration were examined using medical insurance data from the National Database of Health Insurance Claims and Specific Health Checkups of Japan issued from April 2012 to March 2019. RESULTS: The hip fracture group comprised 677,480 women and 264,003 men, the vertebral fracture group comprised 703,247 women and 251,542 men, and the mixed fracture group comprised 3614 women and 1055 men. Test rates were 14.1%, 25.3%, and 17.6% prior to fracture registration (pre-registration) and 22.3%, 43.6%, and 28.1% after fracture registration (post-registration) in the hip, vertebral, and mixed fracture groups, respectively. Moreover, pre-registration treatment rates were 21.2%, 33.5%, and 30.7%, while post-registration rates were 31.6%, 61.7%, and 46.6% in the hip, vertebral, and mixed fracture groups, respectively. All fracture groups showed a tendency for decreased post-registration test and treatment rates among those aged over 80 years old, with men having lower rates. Moreover, 184,180 (19.4% of whom received new treatment) and 707,263 (23.8% of whom received new treatment) patients with and without polypharmacy underwent treatment after registration, respectively. CONCLUSION: To bridge the care gap following fractures, medical professionals should change their perception regarding osteoporosis treatment in patients with hip fractures, elderly individuals undergoing polypharmacy, and males.
Test and treatment rates for osteoporosis in Japan aimed at preventing secondary fragility fractures were insufficient. Those who suffered hip fractures had approximately half the rates of those who suffered vertebral fractures, with such rates being lower among those over 80 years old and males. PURPOSE: The present study aimed to examine the care gap for secondary fracture prevention in Japan given the few large-scale studies regarding the matter. METHODS: Changes in bone mineral density testing (test rate) and osteoporosis pharmacotherapy administration (treatment rate) rates before and after hip and vertebral fracture registration were examined using medical insurance data from the National Database of Health Insurance Claims and Specific Health Checkups of Japan issued from April 2012 to March 2019. RESULTS: The hip fracture group comprised 677,480 women and 264,003 men, the vertebral fracture group comprised 703,247 women and 251,542 men, and the mixed fracture group comprised 3614 women and 1055 men. Test rates were 14.1%, 25.3%, and 17.6% prior to fracture registration (pre-registration) and 22.3%, 43.6%, and 28.1% after fracture registration (post-registration) in the hip, vertebral, and mixed fracture groups, respectively. Moreover, pre-registration treatment rates were 21.2%, 33.5%, and 30.7%, while post-registration rates were 31.6%, 61.7%, and 46.6% in the hip, vertebral, and mixed fracture groups, respectively. All fracture groups showed a tendency for decreased post-registration test and treatment rates among those aged over 80 years old, with men having lower rates. Moreover, 184,180 (19.4% of whom received new treatment) and 707,263 (23.8% of whom received new treatment) patients with and without polypharmacy underwent treatment after registration, respectively. CONCLUSION: To bridge the care gap following fractures, medical professionals should change their perception regarding osteoporosis treatment in patients with hip fractures, elderly individuals undergoing polypharmacy, and males.
Authors: George Ioannidis; Alexandra Papaioannou; Wilma M Hopman; Noori Akhtar-Danesh; Tassos Anastassiades; Laura Pickard; Courtney C Kennedy; Jerilynn C Prior; Wojciech P Olszynski; Kenneth S Davison; David Goltzman; Lehana Thabane; Amiran Gafni; Emmanuel A Papadimitropoulos; Jacques P Brown; Robert G Josse; David A Hanley; Jonathan D Adachi Journal: CMAJ Date: 2009-08-04 Impact factor: 8.262
Authors: T Gold; Setareh A Williams; Richard J Weiss; Yamei Wang; Christopher Watkins; James Carroll; Chloe Middleton; Stuart Silverman Journal: J Drug Assess Date: 2019-10-09
Authors: Paul James Mitchell; Seng Bin Ang; Leilani Basa Mercado-Asis; Reynaldo Rey-Matias; Wen-Shiang Chen; Leon Flicker; Edward Leung; David Choon; Sankara Kumar Chandrasekaran; Jacqueline Clare Therese Close; Hannah Seymour; Cyrus Cooper; Philippe Halbout; Robert Daniel Blank; Yanling Zhao; Jae-Young Lim; Irewin Tabu; Maoyi Tian; Aasis Unnanuntana; Ronald Man Yeung Wong; Noriaki Yamamoto; Ding-Cheng Chan; Joon Kiong Lee Journal: Arch Osteoporos Date: 2022-08-20 Impact factor: 2.879